Immune checkpoint inhibitors increase T cell immunity during SARS-CoV-2 infection

The COVID-19 pandemic has spread worldwide, yet the role of antiviral T cell immunity during infection and the contribution of immune checkpoints remain unclear. By prospectively following a cohort of 292 patients with melanoma, half of which treated with immune checkpoint inhibitors (ICIs), we iden...

Descripción completa

Detalles Bibliográficos
Autores principales: Yatim, Nader, Boussier, Jeremy, Tetu, Pauline, Smith, Nikaïa, Bruel, Timothée, Charbit, Bruno, Barnabei, Laura, Corneau, Aurélien, Da Meda, Laetitia, Allayous, Clara, Baroudjian, Barouyr, Jebali, Majdi, Herms, Florian, Grzelak, Ludivine, Staropoli, Isabelle, Calmettes, Vincent, Hadjadj, Jerome, Peyrony, Olivier, Cassius, Charles, LeGoff, Jerome, Kramkimel, Nora, Aractingi, Selim, Fontes, Magnus, Blanc, Catherine, Rieux-Laucat, Frederic, Schwartz, Olivier, Terrier, Benjamin, Duffy, Darragh, Lebbé, Celeste
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373136/
https://www.ncbi.nlm.nih.gov/pubmed/34407944
http://dx.doi.org/10.1126/sciadv.abg4081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373136/
https://www.ncbi.nlm.nih.gov/pubmed/34407944
http://dx.doi.org/10.1126/sciadv.abg4081

Ejemplares similares